InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent SystemGlobeNewsWire • 10/15/24
InspireMD Gains FDA Premarket Approval for CGuard Prime Carotid StentZacks Investment Research • 10/10/24
InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent SystemGlobeNewsWire • 10/07/24
NSPR Stock Declines Despite PMA Application Submission for CGuardZacks Investment Research • 09/17/24
InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent SystemGlobeNewsWire • 09/16/24
InspireMD Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 08/06/24
InspireMD Congratulates CREST-2 Investigators on Completion of Trial EnrollmentGlobeNewsWire • 08/05/24
InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6thGlobeNewsWire • 07/30/24
InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024GlobeNewsWire • 05/28/24
InspireMD Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/14/24
InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14thGlobeNewsWire • 05/07/24
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/03/24
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024GlobeNewsWire • 03/26/24
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 03/06/24
InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6thGlobeNewsWire • 02/28/24
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection SystemGlobeNewsWire • 02/12/24
InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory FrameworkGlobeNewsWire • 01/31/24